Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.
Rats were administered daily for 8 days with increasing doses (2-12 mg/kg/day) of delta9-tetrahydrocannabinol (delta9-THC) and than challenged with different doses of SR141716A, an antagonist of cannabinoid receptors. SR141716A dose dependently reduced dialysate dopamine (DA) in the nucleus accumbens shell and precipitated a physical withdrawal syndrome. No such effects were obtained after administration of SR141716A to saline controls.
Tanda
G
G
Department of Toxicology and Consiglio Nazionale delle Ricerche, Center for Neuropharmacology, University of Cagliari, Italy.
Loddo
P
P
Di Chiara
G
G
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002186:Cannabinoids / Q000037:antagonists & inhibitors; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D013759:Dronabinol / Q000494:pharmacology* / Q000633:toxicity; D006213:Hallucinogens / Q000494:pharmacology* / Q000633:toxicity; D008297:Male; D017551:Microdialysis; D009714:Nucleus Accumbens / Q000187:drug effects* / Q000502:physiology; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000037:antagonists & inhibitors; D000077285:Rimonabant; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology; D019966:Substance-Related Disorders / Q000503:physiopathology*
D002186:Cannabinoids; D006213:Hallucinogens; D010880:Piperidines; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; D013759:Dronabinol; D000077285:Rimonabant; D004298:Dopamine